Give this fluoroquinolone antibiotic for bone, lower respiratory tract, skin, and urinary tract infections. Food and Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, tax rate assumptions, availability of raw materials and finished products, the regulatory environment, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission. The approval of Tramadol HCl, 50mg tablets is tablet ultram the 8th approval received by Eon Labs in 2002. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that ANDA filings and approvals will be completed and obtained as anticipated. The AB-rated generic version of RW Johnson's Ultram is available in bottles of 100 and tablet ultram 500 for the management of moderate to moderately severe pain. Copies of this and other news releases may be obtained free of charge from IVAX' web site at http://www. Johnson's Ultram(R), is approximately $550 million according to Tablet ultram the IMS Data. These factors and additional information are discussed in the Company's filings with the Securities and tablet ultram exchange Commission and statements in this release should be evaluated in light of these important factors.
The company expects shipments to begin immediately. Business Editors/Health & Medical Writers IVAX Corporation (AMEX:IVX) (LSE:IVX.

L) announced today that it will immediately begin selling tramadol hydrochloride 50 Tablet ultram mg tablets through its wholly owned subsidiary, IVAX Pharmaceuticals, Inc. , now that FDA approval of the Abbreviated New Drug Application (ANDA) for this product has been received. IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products tablet ultram in the U. Ortho-McNeil has retained an option for Ultram(R) ER for other jurisdictions, excluding Canada and Europe.

Tablet ultram private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the beliefs and expectations of management. The combined intellectual property of Biovail, Ortho-McNeil and Purdue provides patent protection through 2014 for Biovail's formulation, which may extend the branded market opportunity for Ultram(R) ER. For example, statements about the Company's operations, capital-raising transactions and financial accounting, the current or expected market size for its products, the success of current or future product offerings, the research and development efforts and the Company's ability to file for tablet ultram and obtain U. Tramadol's minimal Tablet ultram propensity to induce adverse effects is an advantage over morphine-like agents. And Puerto Rico under the brand names Ultram(R) ER and Ultram(R) ODT, respectively. Investors are cautioned that forward-looking statements, including the statements regarding IVAX' pending ANDAs and tentative approvals and filing schedule for ANDA submissions, involve risks and uncertainties which may affect the company's business and prospects, including the risks that the launch of tramadol hydrochloride tablets in 50 mg strength will be delayed; that the compounds and products in the IVAX' research pipeline will not be successfully developed, will not receive regulatory approval or will not be successfully commercialized; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; that IVAX may not receive approval of its pending ANDAs or final approval of its tentatively approved ANDAs, or that if approved, the products will not be successfully commercialized; that IVAX may not file any additional ANDAs; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's 2001 Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.